1. South Korea Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Onconic Therapeutics

Onconic Therapeutics

476060.KQ
Onconic TherapeuticsKR flagKOSDAQ
17,390.00
KRW
-220.00
- -
192.45BMarket Cap
Onconic Therapeutics
476060.KQ
(KOSDAQ)

Recent

price

17,390.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2021
2022
2023
2024
2025
TTM
FRC
26.2
41.09
910.47
453.72
1,214.37
1,514.63
Revenue per Share
-6,614
-6,242.25
72.75
-247.45
359
458.13
Basic EPS, GAAP
-3,871.55
-7,585.97
128.97
-244.07
252.29
302.13
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
Dividend per Share
-6,709.05
-12,888.67
-1,216.3
-1,031.06
1,112.82
1,251.91
Book Value per Share
-3,485.14
-9,489.99
-851.49
1,712.88
1,638.5
1,792.26
Tangible Book Value per Share
2
2
23
33
44
44
Basic Weighted Avg Shares
60
95
21,056
14,838
53,392
67,205
Sales/Revenue/Turnover
-13,903.24
-15,618.48
10.6
-32.33
23.63
23.25
Operating Margin (%)
183
201
460
453
528
412
Depreciation Expense
-15,149
-14,432
1,682
-8,093
15,784
20,328
Net Income, GAAP
- -
- -
- -
- -
- -
0.09
Effective Tax Rate (%)
-25,247.72
-15,191.48
7.99
-54.54
29.56
30.25
Profit Margin (%)
18,520
1,581
-26,250
47,369
60,214
67,771
Working Capital
54
- -
199
120
45
57
LT Debt
-7,978
-21,937
-19,690
56,019
72,039
79,524
Total Equity
- -
- -
- -
- -
- -
22.57
Return on Invested Capital (%)
- -
- -
- -
- -
- -
54.86
Return on Capital (%)
- -
- -
- -
- -
- -
55.11
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
124
81
58
LT Borrowings
- -
- -
- -
LT Finance Leases
48
45
57
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
44
44
- -
Market Capitalization
4,513,651
1,713,435
934,002

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
65,425
63,837
75,764
Cash, Cash Equivalents & STI
53,587
52,735
57,305
Accounts Receivable, Net
8,703
10,531
17,863
Inventories
- -
- -
- -
Total Current Liabilities
4,951
3,623
7,992
Payables & Accruals
- -
- -
- -
ST Debt
124
81
58
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
28.6%
Free Cash Flow
- -
- -
-238.96%
Net Income, GAAP
- -
- -
-295.04%
Sales/Revenue/Turnover
- -
- -
259.82%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,320
2,695
1,987
8,837
14,838
2025
9,169
9,432
19,213
15,577
53,392
2026
22,982
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-132
-242
-392.75
- -
-247.45
2025
10.75
-3.54
212.4
- -
359
2026
143
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Pharmosa Biopharm Inc. (6875.TWO)
Jiangsu Recbio Technology Co., Ltd. (2179.HK)
Marinus Pharmaceuticals, Inc. (MRNS)
Midatech Pharma plc (MTPH.L)
PsyBio Therapeutics Corp. (PSYBF)
Alpine Immune Sciences, Inc. (ALPN)
Business
Onconic Therapeutics Inc Onconic Therapeutics Inc. (476060.KQ) engages in the research, development, and commercialization of innovative biopharmaceuticals focused on cancer treatments, gastrointestinal disorders, and related therapies in South Korea. The company offers Zastaprazan (OCN-101, branded as Jaqbo or Zastaprazan citrate), a potassium-competitive acid blocker approved for erosive gastroesophageal reflux disease and gastric acid-related conditions; OCN-201 (JPI-547), an anticancer agent; JP-1366 (Nesuparib), a poly ADP-ribose polymerase and tankyrase inhibitor in phase 2 for pancreatic cancer, epithelial ovarian cancer, and other solid tumors including non-small cell lung cancer; and pipeline candidates targeting DNA damage response, immuno-oncology, peptic ulcers, and digestive diseases based on small molecules. Founded in 2020 and headquartered at 11F, 12 Teheranro-26-gil, Gangnam-gu, Seoul, South Korea, Onconic Therapeutics operates primarily in the biotechnology sector, serving global markets with high unmet medical needs through its emphasis on next-generation drugs expecting at least two approvals within three years; it functions as a subsidiary of Jeil Pharma Holdings. Recent developments include positive phase 3 results for Jaqbo (Zastaprazan) announced at Digestive Disease Week 2024, leading to regulatory approval by South Korea's Ministry of Food and Drug Safety as the country's 37th domestically developed new drug; a distribution partnership with Laboratorios Sanfer for Jaqbo launch across 19 Latin American countries; KOSDAQ listing in December 2024; and ongoing clinical advancements for Nesuparib in multiple oncology indications.